• Please log in or register to access this feature.

Brief Report

Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes†

  1. Sigurd D. Süssmuth MD1,
  2. Ingo Uttner PhD1,
  3. Bernhard Landwehrmeyer MD1,
  4. Elmar H. Pinkhardt MD1,
  5. Johannes Brettschneider MD1,
  6. Axel Petzold MD PhD2,
  7. Bernd Kramer MD1,
  8. Jörg B. Schulz MD3,
  9. Christian Palm MD1,
  10. Markus Otto MD1,
  11. Albert C. Ludolph MD1,
  12. Jan Kassubek MD1,
  13. Hayrettin Tumani MD1,*

Article first published online: 29 JUN 2010

DOI: 10.1002/mds.22895

Issue

Movement Disorders

Movement Disorders

Volume 25, Issue 9, pages 1284–1288, 15 July 2010

Additional Information

How to Cite

Süssmuth, S. D., Uttner, I., Landwehrmeyer, B., Pinkhardt, E. H., Brettschneider, J., Petzold, A., Kramer, B., Schulz, J. B., Palm, C., Otto, M., Ludolph, A. C., Kassubek, J. and Tumani, H. (2010), Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. Mov. Disord., 25: 1284–1288. doi: 10.1002/mds.22895

Author Information

  1. 1

    Department of Neurology, University of Ulm, Ulm, Germany

  2. 2

    Deparment of Neuroimmunology, Institute of Neurology, Queen Square, London, UK

  3. 3

    Department of Neurodegeneration and Restorative Research, Center for Neurological Medicine, University of Göttingen, Göttingen, Germany

*Department of Neurology, University of Ulm, Oberer Eselsberg 45, D-89081 Ulm, Germany

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 19 JUL 2010
  2. Article first published online: 29 JUN 2010
  3. Manuscript Accepted: 26 OCT 2009
  4. Manuscript Revised: 5 OCT 2009
  5. Manuscript Received: 20 APR 2009

Funded by

  • Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS)
  • European Union 5th Framework programme
  • QLG1-CT-2000-01262
  • Sanofi-Aventis

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (560K)

Keywords:

  • cerebrospinal fluid;
  • biomarker;
  • progressive supranuclear palsy;
  • Richardson's syndrome;
  • PSP-P;
  • multiple system atrophy

Abstract

To evaluate cerebrospinal fluid (CSF) proteins reflecting processes of neurodegeneration and glial activation in progressive supranuclear palsy (PSP; Richardson's syndrome, n = 20; PSP-Parkinsonism, n = 7) and multiple system atrophy (MSA, n = 25), we analyzed tau, phosphorylated tau, amyloid-beta1–42 (Aβ1–42), Aβ1–40, glial fibrillary acidic protein (GFAP), and CSF routine variables. Individuals with PSP-Parkinsonism and MSA had elevated tau levels when compared with Richardson's syndrome, Parkinson's disease (PD), and age-matched controls (P ≤ 0.001). Ratios of P-tau/T-tau were significantly different in Parkinsonian syndromes. CSF Aβ1–42 was decreased only in patients with Richardson's syndrome. In a subset of Parkinsonian syndromes, we found elevated GFAP concentrations and increased CSF/serum albumin ratios. There were no correlations between biomarker concentrations and clinical scores in any of the diseases. In conclusion, this preliminary data show that changes in CSF tau and Aβ1–42 may indicate different protein processing in PSP patients and might, therefore, be relevant in the differentiation of PSP subtypes. © 2010 Movement Disorder Society

View Full Article (HTML) Get PDF (560K)